umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
VEGF and tPA co-expressed in malignant glioma
Umeå University, Faculty of Medicine, Department of Radiation Sciences.
Umeå University, Faculty of Medicine, Department of Radiation Sciences.
Umeå University, Faculty of Medicine, Department of Radiation Sciences.
Umeå University, Faculty of Medicine, Department of Radiation Sciences.
Show others and affiliations
1997 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 36, no 6, 615-618 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
1997. Vol. 36, no 6, 615-618 p.
Identifiers
URN: urn:nbn:se:umu:diva-3720OAI: oai:DiVA.org:umu-3720DiVA: diva2:142551
Available from: 2009-01-07 Created: 2009-01-07 Last updated: 2010-08-19Bibliographically approved
In thesis
1. Experimental therapies of malignant glioma: with emphasis on angiogenesis inhibition
Open this publication in new window or tab >>Experimental therapies of malignant glioma: with emphasis on angiogenesis inhibition
2008 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Malignant glioma consists of a group of diseases where the localisation and the nature of the disease makes treatment an extreme challenge. Two important biological features of malignant glioma cells are their infiltrative growth and their ability to induce angiogenesis. Glioma cells migrate extensively behind the blood-brain barrier and infiltrate the surrounding brain making radical treatment with surgery and radiotherapy almost impossible.

The aims of this thesis were to investigate factors of importance for glioma cell migration and angiogenesis and to evaluate if an anti-angiogenesis approach alone or in combination with current treatment modalities could inhibit glioma growth. For this purpose we used the BT4C orthotopic rat glioma model and investigated treatment effects of the vascular endothelial growth factor (VEGF) receptor-2 and epidermal growth factor (EGF) receptor tyrosine kinase inhibitor ZD6474 alone or in combination with temozolomide or radiotherapy. Altered protein expression pattern after anti-angiogenesis treatment was measured using a mass-spectrometric proteomic method, followed by multivariate data-analysis.

The tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and VEGF showed altered temporal and spatial mRNA expression during glioma progression. In early stages of tumour progression the expression was found throughout the tumour while in later stages, the expression was more predominant in the invasive tumour border.

ZD6474 in monotherapy significantly inhibited tumour growth in the BT4C glioma model. The effect was further enhanced when combined with radiotherapy or temozolomide. Using mass-spectrometric methods an altered protein expression pattern after ZD6474 treatment was observed implicating the possibility to use proteomic methods for finding predictive biomarkers for anti-angiogenesis treatment.

In conclusion, this thesis demonstrates a co-expression of factors important for glioma growth and angiogenesis and that treatment with an angiogenesis inhibitor has additive effects on glioma growth when combined with radiotherapy and chemotherapy. Finally, an altered protein expression pattern after anti-angiogenesis treatment is evident and detectable. Hopefully this work will contribute to and encourage further research to reach a better understanding of how to combine and evaluate different treatment approaches in malignant glioma.

Place, publisher, year, edition, pages
Umeå: Umeå universitet, 2008. 76 p.
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 1219
Keyword
glioma, angiogenesis, VEGF, tyrosinekinaseinhibitor, ZD6474, plasminogenactivator, tPA, uPA, proteomics
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-1955 (URN)978-91-7264-667-4 (ISBN)
Public defence
2009-01-23, Betula, 6M, Norrlands Universitets Sjukhus, Umeå, 13:00 (English)
Opponent
Supervisors
Available from: 2009-01-07 Created: 2009-01-07 Last updated: 2012-04-03Bibliographically approved

Open Access in DiVA

No full text

Other links

http://dx.doi.org/10.3109/02841869709001324

Search in DiVA

By author/editor
Lindgren, MariaJohansson, MikaelJonsson, YvonneBergenheim, A. TommyHenriksson, Roger
By organisation
Department of Radiation SciencesDepartment of Pharmacology and Clinical Neuroscience
In the same journal
Acta Oncologica

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 108 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf